![David Lee](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David K.
Lee currently works at Servier Pharmaceuticals LLC, as Chief Executive Officer from 2018.
Mr. Lee also formerly worked at iTeos Therapeutics, Inc., as Independent Director from 2023 to 2025 and Shire International GmbH (Switzerland), as Global Head-Oncology & Rare Diseases from 2015 to 2018.
Mr. Lee received his undergraduate degree from Harvard University and Masters Business Admin degree from Harvard Business School.
| Unternehmen | Position | Beginn |
|---|---|---|
Servier Pharmaceuticals LLC
 Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Operates as a pharmaceuticals company | Vorstandsvorsitzender | 01.09.2018 |
| Unternehmen | Position | Ende |
|---|---|---|
| ITEOS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 28.08.2025 |
Shire International GmbH (Switzerland)
 Shire International GmbH (Switzerland) Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceuticals | Corporate Officer/Principal | 01.09.2018 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
| Private Unternehmen | 5 |
|---|---|
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shire International GmbH (Switzerland)
Shire International GmbH (Switzerland) Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets pharmaceuticals | Health Technology |
Servier Pharmaceuticals LLC
Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Operates as a pharmaceuticals company | Health Technology |
iTeos Therapeutics, Inc.
 iTeos Therapeutics, Inc. BiotechnologyHealth Technology Develops immunomodulators for cancer treatments | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen
